熱門資訊> 正文
Pulse Biosciences报告第二季度业绩
2024-08-13 04:14
- Pulse Biosciences press release (NASDAQ:PLSE): Q2 Total GAAP costs and expenses, representing research and development and general and administrative expenses, for the three months ended June 30, 2024, were $11.7 million.
- Non-GAAP costs and expenses for the three months ended June 30, 2024, were $9.4 million.
- Cash and cash equivalents totaled $26.2 million as of June 30, 2024. The cash balance as of June 30, 2024 does not include $60 million in proceeds received from the rights offering that closed in July of 2024.
- Cash used in the second quarter of 2024 was $8.7 million.
More on Pulse Biosciences
- Pulse Biosciences Stock: Signs Of Life Following Q1 Update
- Pulse stock rallies 22% on FDA breakthrough designation
- Pulse Biosciences announces updated timing of rights offering for up to $60M
- Financial information for Pulse Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
